Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – (ITM) and the Institut Laue-Langevin (ILL) have prolonged their partnership, initially formed in 2009, for the manufacturing of medical radioisotopes. As part of the extended agreement, ITM will be given priority access to half of the neutron irradiation capacity available at ILL’s High-Flux Reactor, its neutron irradiation facility. This access will be used for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a crucial medical radioisotope employed in radiopharmaceutical therapies for cancer treatment and diagnosis. As the world’s leading producer of n.c.a. Lu-177, ITM is dedicated to maintaining and growing its robust manufacturing and production capabilities to meet the rising demand for this essential medical radioisotope.

Dr. Andrew Cavey, CEO of ITM, stated, “The collaboration between ITM and ILL began in 2009, during the early stages of the radiopharmaceutical industry. Our priority access to ILL’s renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 increases and our radiopharmaceutical pipeline advances.”

The high neutron flux of ILL’s reactor enables ITM to achieve a high yield of Lu-177 and promotes sustainable production of the medical radioisotope by minimizing the use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM significantly contributes to the geographic and industrial benefits that ILL provides to its funding countries, encouraging innovation and supporting advancements in radiopharmaceutical research and production.

Dr. Ken Andersen, Director of the Institut Laue-Langevin, added, “ILL operates the world’s foremost neutron source for research in neutron scattering and in nuclear and particle physics. Additionally, ILL’s reactor offers irradiation positions with exceptionally high neutron flux, utilized for both fundamental research and the production of radionuclides for medical purposes. ILL is proud of its long-standing collaboration with ITM, regularly performing irradiations of Ytterbium-176 targets for ITM over the past 15 years, and anticipates an even closer partnership in the years ahead.”


About Radiopharmaceutical Therapy (RPT)
Radiopharmaceutical Therapy (RPT) is an emerging category of cancer treatments designed to deliver radiation directly to tumors while reducing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by combining a therapeutic radioisotope, such as Lutetium-177 or Actinium-225, with a targeting molecule (e.g., peptide, antibody, small molecule) that can accurately identify tumor cells and attach to tumor-specific characteristics, like receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation with the aim of destroying tumor tissue. This precise localization allows for targeted treatment with potentially minimal impact on healthy surrounding tissue.

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is committed to delivering a new generation of radiomolecular precision therapeutics and diagnostics for difficult-to-treat tumors. Our goal is to meet the needs of cancer patients, clinicians, and our partners through excellence in development, production, and global supply. With improved patient benefit as the core principle, ITM advances a broad precision oncology pipeline, including two phase III studies, by combining the company’s high-quality radioisotopes with various targeting molecules. Leveraging nearly two decades of pioneering radiopharma expertise, a central industry position, and an established global network, ITM strives to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life.

About the ILL, Institut Laue-Langevin
The ILL is the world’s leading facility for neutron science and technology. It delivers the most intense neutron beams globally to its unique suite of 43 state-of-the-art neutron scattering instruments, providing a unique tool for examining the fundamental nature of matter. Annually, approximately 1500 international researchers visit the ILL to conduct over 1000 cutting-edge experiments across various disciplines, including physics, chemistry, biology, materials science, and engineering. In addition to its impact on scientific research and educational excellence, the ILL promotes innovation in health, energy, the environment, and quantum materials. The ILL has been involved in the production of radioisotopes for medical applications for over 15 years. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, with the UK joining a few years later. Currently, 13 countries fund the facility for their research communities.

ITM Contact
Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:

ILL Contact
Radionuclide Production
Ulli Köster 
Phone: (+33) (0)4 76 20 71 54
Email:

Communications
Catarina Espirito Santo
Phone: (+33) (0)4 76 20 71 07
Email:

Attachment